Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Etanercept in the longterm treatment of patients with ankylosing spondylitis
Journal of Rheumatology, 06/11/09
Dijkmans B et al. – In the two year study period, etanercept was clinically effective and well tolerated, with no unexpected safety findings, in pts with ankylosing spondylitis (AS).
Methods- An evaluation of the 2-yr efficacy and safety of etanercept in pts with AS
- A 96-wk open-label extension study, which followed a 12-wk double-blind placebo-controlled trial
- Pts were treated with etanercept 25 mg x2/wk
- In all, 81 pts were enrolled (96% of the participants from the double-blind study)
- Key efficacy measures: improvement using-
- Assessment in Ankylosing Spondylitis 20% (ASAS20) criteria
- Bath Ankylosing Spondylitis Functional Index (BASFI), and
- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
- Radiographic progression was evaluated using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) method
- Percentage of responders, by ASAS20 criteria, remained relatively constant in pts who received etanercept during the 12-wk double-blind study
- More pts from the placebo group became responders after being switched to etanercept
- A similar trend was also observed using the ASAS40 and ASAS5/6 criteria, the BASFI, and the BASDAI
- Most pts had no change from baseline in mSASSS values
- Etanercept was well tolerated:
- Most frequent AEs were injection site reactions, and headache
- Most frequent infections were upper respiratory tract infections and flu syndrome
Related Articles
Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor
Modern Rheumatology, 10/05/09
Relevance Score: 69%
Erythrocyte sedimentation rate, CRP level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis
Arthritis Care and Research, 11/02/09
Relevance Score: 68%
Uncommon case of ankylosing spondylitis associated with spontaneous occurring hypoparathyroidism
Rheumatology International, 11/11/09
Relevance Score: 67%
Concomitant cervical and thoracic spinal fractures in ankylosing spondylitis: A case report and review of literature
Injury Extra, 11/05/09
Relevance Score: 67%
A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis
Rheumatology International, 10/27/09
Relevance Score: 67%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Can tumor necrosis factor inhibitors be safely used in pregnancy?
Journal of Rheumatology, 12/17/09
The effect of anti-TNF agent on oxidation status in patients with ankylosing spondylitis
Clinical Rheumatology, 12/17/09
Unresponsiveness to colchicine therapy in patients with familial Mediterranean fever homozygous for the M694V mutation
Journal of Rheumatology, 12/17/09
Today in Spondylarthropathies...keeping you current
Receive free subspecialty "5-minute updates" via email
The effect of anti-TNF agent on oxidation status in patients with ankylosing spondylitis
Clinical Rheumatology, 12/17/09
Programmed cell death 1 gene polymorphisms is associated with ankylosing spondylitis in Chinese Han population
Rheumatology International, 12/16/09
Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-&alpha blocker therapy
Rheumatology, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


